APLS today

$41.03-$0.03 (-0.07%)close May 13, 2026

Trend

—

Key levels

Resistance$41.94

Resistance$41.55

Support$40.95

Support$40.85

Latest news & SEC filings

No headlines in the last 90 days.

Nasdaq · Healthcare

Apellis Pharmaceuticals, Inc. (APLS)

$41.03-0.03 (-0.07%)
HOLDGrade: BRisk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
40.5440.6840.8340.9741.03Apr 10Apr 20Apr 28May 6
High41.07
Low41.03
Open41.06
Volume55.72M
Avg Vol6.80M
VWAP41.04
30d High41.12
30d Low40.39
30d Chg+1.58%
See full chart with real-time data

What Is the Price Target for APLS?

SEPT Low Target

$34.85

SEPT Mid Target

$41.00

SEPT High Target

$47.15

Analyst Consensus

$41.00

Current: $41.05Upside: -0.1%Confidence: 85%Method: Analyst Consensus

Is APLS a Buy or Sell Right Now?

55
Investability Score
HOLD12-18 months

Thesis

  • •Revenue growing 28.5% YoY with STRONG trend — consistent growth.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for APLS.

Start Free Trial →

Is APLS Overvalued or Undervalued?

Valuation Verdict

N/A

Methods Used

N/A

Fair Value

$41.00

25

Moat Score

NONE

6/9

Piotroski Score

2.5

Altman Z-Score

What Is Smart Money Doing with APLS?

Insider Signal

SELLING

0 buys / 9 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

NEUTRAL

Short Squeeze Risk

LOW

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

APLS Growth Story

Revenue YoY

28.5%

3yr Revenue CAGR

N/A%

EPS Growth YoY

112.5%

FCF Growth YoY

151.0%

Revenue Trend

STRONG

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Apellis Pharmaceuticals, Inc. (APLS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

Sign Up Free — Download AI Report PDF →

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

Compare SEPT with other platforms

SEPT vs TradingViewSEPT vs BloombergSEPT vs Unusual WhalesSEPT vs SpotGammaSEPT vs TrendSpiderAI Trading Platforms Compared
What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

About SEPT Investing

SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

APLS — frequently asked questions

What is APLS stock price today?

Apellis Pharmaceuticals, Inc. (APLS) is at $41.03, down 0.07% (-$0.03) at the May 13, 2026 close.

What is the APLS price target?

The average analyst price target for APLS is $41.00, ranging from $41 to $41, based on 6 analysts. Latest: Wells Fargo downgrade on Apr 17, 2026.

What do analysts rate APLS?

Analyst ratings for APLS: 0 Buy, 2 Hold, 6 Sell — consensus Sell.

What are APLS support and resistance levels?

Support: $40.95, $40.85, $40.77. Resistance: $41.55, $41.94, $42.47.

What are insiders doing with APLS?

Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.